 INDUCTION THERAPY: Patients receive cytarabine intravenously IV on days 1-7, daunorubicin hydrochloride IV on days 1-3, and selinexor orally PO twice weekly from day 1. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity. 